Loading
A phase 1 trial of NG-350A run by Akamis Bio, completed.
Study of NG-350A Plus Pembrolizumab in Metastatic or Advanced Epithelial Tumours (FORTIFY) is a phase 1 interventional study registered as NCT05165433 by Akamis Bio, with 14 participants enrolled, started 2022-04-13, primary completion reached 2025-08-29. Conditions recorded: Epithelial Tumor, Metastatic Cancer. Interventions recorded: NG-350A plus Pembrolizumab.
Shares NG-350A, Akamis Bio and the tag pipeline.
Shares NG-350A, Akamis Bio and the tag pipeline.
Shares Akamis Bio and the tag pipeline.
Shares NG-350A, Akamis Bio.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/